Daan P. Hurkmans

1.0k citations

27 papers · 700 indexed · h-index 15

Oncology top 5%
- Cancer Immunotherapy and Biomarkers 21
- Pancreatic and Hepatic Oncology Research 6
- CAR-T cell therapy research 4
- Cancer Diagnosis and Treatment 3
- Colorectal Cancer Treatments and Studies 2
Transplantation top 10%
Immunology
- Immunotherapy and Immune Responses 5
Cancer Research
- Cancer Genomics and Diagnostics 3
Pulmonary and Respiratory Medicine
- Lung Cancer Treatments and Mutations 4

Co-authors: Joachim G.J.V. Aerts Ron H.J. Mathijssen Stijn L.W. Koolen Astrid A.M. van der Veldt Reno Debets Edwin A. Basak Esther Oomen‐de Hoop Sander Bins
Cited by: Oncology Transplantation Immunology
Journals: Journal of Clinical Oncology (4 papers)Clinical Cancer Research (1 paper)Annals of Oncology (3 papers)
Partner nations: Netherlands Switzerland Italy

In The Last Decade

Daan P. Hurkmans

25 papers receiving 694 citations

Peers

Countries citing papers authored by Daan P. Hurkmans

Since Specialization

Citations

This map shows the geographic impact of Daan P. Hurkmans's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daan P. Hurkmans with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daan P. Hurkmans more than expected).

Fields of papers citing papers by Daan P. Hurkmans

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daan P. Hurkmans. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daan P. Hurkmans. The network helps show where Daan P. Hurkmans may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Daan P. Hurkmans, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Daan P. Hurkmans Line = papers co-authored together Daan P. Hurkmans links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Associations between patient and disease characteristics and severe adverse events during immune checkpoint inhibitor treatment: An observational study European Journal of Cancer ·Edwin A. Basak,Niels S. Vermeer,Karlijn de Joode,Daan P. Hurkmans,Dorian E.M. Velthuis,Esther Oomen‐de Hoop,Marco W.J. Schreurs,Sander Bins,Stijn L.W. Koolen,Reno Debets,Astrid A.M. van der Veldt,Joachim G.J.V. Aerts,Arjen Joosse,Ron H.J. Mathijssen	2022	13
2	Influence of esomeprazole on the bioavailability of afatinib: A pharmacokinetic cross-over study in patients with non-small cell lung cancer Biomedicine & Pharmacotherapy ·G. Veerman,Daan P. Hurkmans,Marthe S. Paats,Esther Oomen‐de Hoop,Cor H. van der Leest,E. Thiel,Joachim G.J.V. Aerts,Roelof W. van Leeuwen,Anne‐Marie C. Dingemans,Ron H.J. Mathijssen	2022	1
3	Germline Variation in PDCD1 Is Associated with Overall Survival in Patients with Metastatic Melanoma Treated with Anti-PD-1 Monotherapy Cancers ·Mirjam de With,Daan P. Hurkmans,Esther Oomen‐de Hoop,Ayoub Lalouti,Sander Bins,Samira El Bouazzaoui,Mandy van Brakel,Reno Debets,Joachim G.J.V. Aerts,Ron H. N. van Schaik,Ron H.J. Mathijssen,Astrid A.M. van der Veldt	2021	9
4	Prospective real-world study on the pharmacokinetics of pembrolizumab in patients with solid tumors Journal for ImmunoTherapy of Cancer ·Daan P. Hurkmans,Sebastiaan D. T. Sassen,Karlijn de Joode,Lisanne Putter,Edwin A. Basak,Annemarie Wijkhuijs,Markus Joerger,Reno Debets,Birgit C. P. Koch,Cor H. van der Leest,Marco W.J. Schreurs,Astrid A.M. van der Veldt,Joachim G.J.V. Aerts,Ron H.J. Mathijssen,Stijn L.W. Koolen	2021	15
5	The prognostic value of weight and body composition changes in patients with non‐small‐cell lung cancer treated with nivolumab Journal of Cachexia Sarcopenia and Muscle ·Juliette Degens,Anne‐Marie C. Dingemans,Anna C. H. Willemsen,Hester A. Gietema,Daan P. Hurkmans,Joachim G.J.V. Aerts,Lizza Hendriks,Annemie M.W.J. Schols	2021	31
6	A Serum Protein Classifier Identifying Patients with Advanced Non–Small Cell Lung Cancer Who Derive Clinical Benefit from Treatment with Immune Checkpoint Inhibitors Clinical Cancer Research ·Mirte Muller,Karlijn Hummelink,Daan P. Hurkmans,Anna-Larissa N. Niemeijer,Kim Monkhorst,Joanna Roder,Carlos Oliveira,Heinrich Röder,Joachim G.J.V. Aerts,Egbert F. Smit	2020	17
7	Overt Thyroid Dysfunction and Anti-Thyroid Antibodies Predict Response to Anti-PD-1 Immunotherapy in Cancer Patients Thyroid ·Edwin A. Basak,Jan W.M. van der Meer,Daan P. Hurkmans,Marco W.J. Schreurs,Esther Oomen‐de Hoop,Astrid A.M. van der Veldt,Sander Bins,Arjen Joosse,Stijn L.W. Koolen,Reno Debets,Robin P. Peeters,Joachim G.J.V. Aerts,Ron H.J. Mathijssen,Marco Medici	2020	64
8	Molecular data show conserved DNA locations distinguishing lung cancer subtypes and regulation of immune genes Lung Cancer ·Daan P. Hurkmans,Menno Tamminga,Bram van Es,Tom Peters,W. Karman,Rogier T. A. van Wijck,Peter J. van der Spek,Tjebbe Tauber,Maureen Los,Anouk van Schetsen,Thu Huong Vu,T. Jeroen N. Hiltermann,Ed Schuuring,Joachim G.J.V. Aerts,Sissy Chen,Harry J.M. Groen	2020	2
9	High-intensity statins are associated with improved clinical activity of PD-1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patients European Journal of Cancer ·Luca Cantini,Federica Pecci,Daan P. Hurkmans,Robert A. Belderbos,Andrea Lanese,Cecilia Copparoni,Sophie Aerts,Robin Cornelissen,Daphne W. Dumoulin,Ilaria Fiordoliva,Silvia Rinaldi,Joachim G.J.V. Aerts,Rossana Berardi	2020	83
10	Granzyme B is correlated with clinical outcome after PD-1 blockade in patients with stage IV non-small-cell lung cancer Journal for ImmunoTherapy of Cancer ·Daan P. Hurkmans,Edwin A. Basak,Nina Schepers,Esther Oomen‐de Hoop,Cor H. van der Leest,Samira El Bouazzaoui,Sander Bins,Stijn L.W. Koolen,Stefan Sleijfer,Astrid A.M. van der Veldt,Reno Debets,Ron H. N. van Schaik,Joachim G.J.V. Aerts,Ron H.J. Mathijssen	2020	51
11	1200P Tyrosine kinase activity profiling as a predictive biomarker for clinical benefit to immune checkpoint inhibition in advanced melanoma and NSCLC Annals of Oncology ·Karlijn de Joode,Harry J.M. Groen,Astrid A.M. van der Veldt,Karijn P.M. Suijkerbuijk,Jan Willem B. de Groot,Rik de Wijn,Daan P. Hurkmans,Dianne M.A. van den Heuvel,Kerstin Schmidt,John P. Groten,Els M.E. Verdegaal,Sjoerd H. van der Burg,Michel M. van den Heuvel,Joachim G.J.V. Aerts,Ellen Kapiteijn,Ron H.J. Mathijssen	2020	1
12	Tumor mutational load, CD8+ T cells, expression of PD-L1 and HLA class I to guide immunotherapy decisions in NSCLC patients Cancer Immunology Immunotherapy ·Daan P. Hurkmans,Merian E. Kuipers,Jasper Smit,Ronald van Marion,Ron H.J. Mathijssen,Piet E. Postmus,Pieter S. Hiemstra,Joachim G.J.V. Aerts,Jan H. von der Thüsen,Sjoerd H. van der Burg	2020	77
13	Impact of Curcumin (with or without Piperine) on the Pharmacokinetics of Tamoxifen Cancers ·Koen G. A. M. Hussaarts,Daan P. Hurkmans,Esther Oomen‐de Hoop,Leonie J. van Harten,Stan Berghuis,Robbert J. van Alphen,Leontine E.A.M.M. Spierings,Quirine C. van Rossum‐Schornagel,Mijntje B. Vastbinder,Ron H. N. van Schaik,Teun van Gelder,Agnes Jager,Roelof W. F. van Leeuwen,Ron H.J. Mathijssen	2019	34
14	Correlation between nivolumab exposure and treatment outcomes in non–small-cell lung cancer European Journal of Cancer ·Edwin A. Basak,Stijn L.W. Koolen,Daan P. Hurkmans,Marco W.J. Schreurs,Sander Bins,Esther Oomen‐de Hoop,Annemarie Wijkhuijs,Ilse den Besten,Stefan Sleijfer,Reno Debets,Astrid A.M. van der Veldt,Joachim G.J.V. Aerts,Ron H.J. Mathijssen	2019	54
15	A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients Journal for ImmunoTherapy of Cancer ·Daan P. Hurkmans,Edwin A. Basak,Tanja van Dijk,Darlene Mercieca,Marco W.J. Schreurs,Annemarie Wijkhuijs,Sander Bins,Esther Oomen‐de Hoop,Reno Debets,Markus Joerger,Arlette E. Odink,Astrid A.M. van der Veldt,Cor H. van der Leest,Joachim G.J.V. Aerts,Ron H.J. Mathijssen,Stijn L.W. Koolen	2019	66
16	Tumour growth rate as a tool for response evaluation during PD-1 treatment for non-small cell lung cancer: a retrospective analysis ERJ Open Research ·Deirdre M.H.J. ten Berge,Daan P. Hurkmans,Ilse den Besten,Jeroen S. Kloover,Ron H.J. Mathijssen,Reno Debets,Egbert F. Smit,Joachim G.J.V. Aerts	2019	23
17	Donor-derived cell-free DNA detects kidney transplant rejection during nivolumab treatment Journal for ImmunoTherapy of Cancer ·Daan P. Hurkmans,Jeroen G. H. P. Verhoeven,Kitty de Leur,Karin Boer,Arjen Joosse,Carla C. Baan,Jan H. von der Thüsen,Ron H. N. van Schaik,Ron H.J. Mathijssen,Astrid A.M. van der Veldt,Dennis A. Hesselink	2019	30
18	CD45RA+CCR7− CD8 T cells lacking co-stimulatory receptors demonstrate enhanced frequency in peripheral blood of NSCLC patients responding to nivolumab Journal for ImmunoTherapy of Cancer ·André Kunert,Edwin A. Basak,Daan P. Hurkmans,Hayri E. Balcıoğlu,Yarne Klaver,Mandy van Brakel,Astrid A. M. Oostvogels,C. B. H. W. Lamers,Sander Bins,Stijn L.W. Koolen,Astrid A.M. van der Veldt,Stefan Sleijfer,Ron H.J. Mathijssen,Joachim G.J.V. Aerts,Reno Debets	2019	43
19	P2.04-47 Tumor Mutational Load, CD8+ T Cells, Expression of PD-L1 and HLA Class I to Guide Immunotherapy Decisions Journal of Thoracic Oncology ·Daan P. Hurkmans,Merian E. Kuipers,Jasper Smit,Ronald van Marion,Ron H.J. Mathijssen,Pieter E. Postmus,Pieter S. Hiemstra,Joachim G.J.V. Aerts,Jan H. von der Thüsen,SH van der Burg	2019	1
20	Blood-based multiplex kinase activity profiling as a predictive marker for clinical response to checkpoint blockade in advanced melanoma. Journal of Clinical Oncology ·Daan P. Hurkmans,Els M.E. Verdegaal,Sabrina A. Hogan,Edwin A. Basak,Dianne M.A. van den Heuvel,Rik de Wijn,Rob Ruijtenbeek,John P. Groten,Reinhard Dummer,Stijn L.W. Koolen,Marij J.P. Welters,Ron H.J. Mathijssen,Ellen Kapiteijn,Joachim G.J.V. Aerts,Mitchell P. Levesque,Sjoerd H. van der Burg	2018	1

About Daan P. Hurkmans

Daan P. Hurkmans is a scholar working on Oncology, Transplantation and Cancer Research, having authored 27 papers that have together received 700 indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (21 papers), Pancreatic and Hepatic Oncology Research (6 papers), Immunotherapy and Immune Responses (5 papers), CAR-T cell therapy research (4 papers), Lung Cancer Treatments and Mutations (4 papers), Cancer Diagnosis and Treatment (3 papers), Cancer Genomics and Diagnostics (3 papers) and Colorectal Cancer Treatments and Studies (2 papers). The work is most often cited by research in Oncology (510 citations), Transplantation (26 citations) and Immunology (196 citations). Daan P. Hurkmans has collaborated with scholars based in Netherlands, Switzerland and Italy. Frequent co-authors include Joachim G.J.V. Aerts, Ron H.J. Mathijssen, Stijn L.W. Koolen, Astrid A.M. van der Veldt, Reno Debets, Edwin A. Basak, Esther Oomen‐de Hoop, Sander Bins, Marco W.J. Schreurs and Stefan Sleijfer. Their work appears in journals such as Journal of Clinical Oncology, Clinical Cancer Research and Annals of Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact